From Our Neurons to Yours

Join us as we dive back into the world of psychedelic medicine with anesthesiologists Boris Heifets and Theresa Lii, who share intriguing new data that sheds light on how ketamine and placebo effects may interact in treating depression.We explore provocative questions like: How much of ketamine's antidepressant effect comes from the drug itself versus the excitement of being in a psychedelics trial? What do we know about how placebo actually works in the brain? And should we view the placebo effect as a feature rather than a bug in psychiatric treatment?Join us as we examine the complex interplay between psychoactive drugs, the brain's own opioid system, and the healing power of hope in mental health care.Related researchPreprint: Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial (medRxiv, 2024)Randomized trial of ketamine masked by surgical anesthesia in patients with depression (Nature Mental Health, 2023)Related episodesPsychedelics, placebo, and anesthetic dreams | Boris Heifets (Part 1) Psychedelics Inside Out: How do LSD and psilocybin alter perception? | Boris Heifets (Part 2)OCD and Ketamine | Carolyn RodriguezPsychedelics and Empathy: Why are psychiatrists taking a fresh look at MDMA? | Rob MalenkaRelated newsResearchers find response to ketamine depends on opioid pathways, but varies by sex (Stanford Medicine, 2024)The rebirth of psychedelic medicine (Wu Tsai Neuro, 2023)Can Psychedelic Drugs Treat Physical Pain? (Scientific American, 2022)Scientists Say A Mind-Bending Rhythm In The Brain Can Act Like Ketamine (NPR, 2020)Get in touchWe're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hostSend us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Today, we are going back into the archives for one of my favorite episodes: We are talking to neuroscientist, entrepreneur, and best-selling author, David Eagleman. We're talking about synaesthesia — and if you don't know what that is, you're about to find out.Special NoteWe are beyond thrilled that From Our Neurons to Yours has won a 2024 Signal Award in the Science Podcast category. It's a big honor — thanks to everyone who voted!---Imagine Thursday. Does Thursday have a color? What about the sound of rain — does that sound taste like chocolate? Or does the sound of a saxophone feel triangular to you? For about 3% of the population, the sharp lines between our senses blend together. Textures may have tastes, sounds, shapes, numbers may have colors. This sensory crosstalk is called synesthesia, and it's not a disorder, just a different way of experiencing the world. To learn about the neuroscience behind this fascinating phenomenon and what it tells us about how our brains perceive the world, we were fortunate enough to speak with David Eagleman, a neuroscientist, author, and entrepreneur here at Stanford who has long been fascinated by synesthesia and what it means about how our perceptions shape our reality.LinksLivewired (book)Incognito (book)Wednesday Is Indigo Blue (book)Neosensory (website)Synesthete.org (website)Inner Cosmos with David Eagleman (podcast)Get in touchWe're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Earlier this year, President Obama's signature BRAIN Initiative, which has powered advances in neuroscience for the past 10 years, had its budget slashed by 40%. Over the past decade, the BRAIN Initiative made roughly $4 billion in targeted investments in more than 1500 research projects across the country and has dramatically accelerated progress tackling fundamental challenges in neuroscience. As we head into the next federal budget cycle, the future of the initiative remains uncertain. Today we take stock of how the BRAIN Initiative transformed neuroscience over the past 10 years, and what the outlook is for the future of the field.To give us an unparalleled behind the scenes view, we are fortunate to have Bill Newsome with us on the show. A world renowned expert in the brain mechanisms of visual perception and decision-making, Bill co-chaired the original BRAIN Initiative planning committee in 2013 (the same year he became the founding director of the Wu Tsai Neurosciences Institute here at Stanford). Don't miss this conversation!Learn MoreAbout the BRAIN Initiative NIH BRAIN Initiative websiteA Leader of Obama's New Brain Initiative Explains Why We Need It (WIRED, April 2013)BRAIN @ 10: A decade of innovation (Neuron, Sept 2024)Reflecting on a decade of BRAIN—10 Institutes and Centers, one mission (NIH BRAIN Blog, Aug 2024)About last year's funding cuts: Understanding the BRAIN Initiative budget (NIH BRAIN Initiative)$278 million cut in BRAIN Initiative funding leaves neuroscientists in limbo (The Transmitter, April 2024)The Future of BRAIN Initiative Funding Remains Unclear (The Transmitter, July 2024)Get in touchWe're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Given the widespread legalization of cannabis for medical and recreational uses, you'd think we'd have a better understanding of how it works. But ask a neuroscientist exactly how cannabinoid compounds like THC and CBD alter our perceptions or lead to potential medical benefits, and you'll soon learn just how little we know.We know that these molecules hijack an ancient signaling system in the brain called the "endocannabinoid" system (translation: the "cannabinoids within"). These somewhat exotic signaling molecules (made of fatty lipids and traveling "backwards" compared to other transmitters) have been deeply mysterious until recently, when new tools made it possible to visualize their activity directly in the brain.So what is the "day job" of the endocannabinoid system — and how does it connect to the dramatic highs that come with taking THC or the medical benefits of CBD? To unpack all this, we're talking this week with neuroscientist Ivan Soltesz, the James Doty Professor of Neurosurgery and Neuroscience at Stanford, and a leading expert on the endocannabinoid system.Learn MoreThe Soltesz Lab"Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy" (Soltesz et al, Nature Reviews Neuroscience, 2015) "Keep off the grass? Cannabis, cognition and addiction" (Parsons et al, Nature Reviews Neuroscience, 2016)"Marijuana-like brain substance calms seizures but increases aftereffects, study finds" (Goldman, Stanford Medicine News, 2021)"Retrograde endocannabinoid signaling at inhibitory synapses in vivo" (Dudok et al, Science, 2024)Vote for us!We are a finalist for a prestigious Signal Award for Best Science Podcast of 2024! Share your love for the show by voting for us in the Listener's Choice category by October 17. Thanks in advance!Get in touch:We're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.